Real-World Visual and Refractive Results of Two Different Presbyopia Correcting Intraocular Lenses

Further Publications

Risk factors in self-reported dissatisfied patients implanted with various presbyopia-correcting intraocular lenses after cataract surgery

BMC Ophthalmol

Jeon W, Yoon CH, Oh JY, Choi HJ, Kim MK

doi: 10.1186/s12886-025-03912-4

Lenses

Two-Year Visual, Refractive, and Anatomical Outcomes of Sutureless Intrascleral One-Piece IOL Fixation: A Prospective Study

Ophthalmol Retina

Marolo P, Parisi G, Conte F, Cimorosi F, Tibaldi D, Fallico M, Toro MD, Borrelli E, Motta L, Vaiano AS, Reibaldi M

doi: 10.1016/j.oret.2025.09.005

Uveitis

Intraocular Inflammation (IOI) Associated with Faricimab Therapy: One-year Real World Outcomes

Retina

Montesel A, Sen S, Preston E, Patel PJ, Huemer J, Hamilton RD, Nicholson L, Papasavvas I, Tucker WR, Yeung I

doi: 10.1097/IAE.0000000000004394

Glaucoma and Ocular Pressure

Time to identify glaucoma progression given real-world visual field testing frequencies in a US nationwide insured population

Ophthalmol Glaucoma

Stagg BC, Brintz BJ, Stein JD, Hess R, Kawamoto K, Jammal AA, Medeiros FA

doi: 10.1016/j.ogla.2025.11.004

Macular Diseases

Treatment Regimens with Ranibizumab in Neovascular Age-Related Macular Degeneration: Real-World Results from the PACIFIC Study

Clin Ophthalmol

Lorenz K, Haritoglou C, Barthelmes D, Sefat AMM, Berk H, Beeke E, Scheffler M, Iwersen M, Müller B, Ziemssen F, members of the PACIFIC study group

doi: 10.2147/OPTH.S512630

Macular DiseasesRetinal Diseases

Visual outcomes and anatomical biomarkers of Faricimab for diabetic macular edema in the J-CREST real-world comparison of naïve and treated eyes

Sci Rep

Murao F, Yanai R, Kusuhara S, Abe Y, Shimura M, Ohara H, Terasaki H, Sugimoto M, Matsubara H, Hirano Y, Kinoshita T, Tsujinaka H, Seki K, Iwase T, Mitamura Y, J-CREST

doi: 10.1038/s41598-025-20300-6

Macular Diseases

Real-World Outcomes of Different Types of Treatment for Diabetic Macular Edema Before and After Approval of Anti-Vascular Endothelium Growth Factor Agents

J Clin Med

Sugimoto M, Chujo S, Kato K, Shimura M, Kitano S, Kusuhara S, Terasaki H, Kondo M, Writing Committee Of Japan-Clinical Retina Study Group J-Crest

doi: 10.3390/jcm13237336

Glaucoma and Ocular Pressure

Prototype master protocol for benchmarking of real-world follow-up data in glaucoma

Acta Ophthalmol

Hujanen P, Tuulonen A, Leinonen S, Vepsäläinen K, Jóhannesson G, Vaajanen A, Lehtonen E, Uusitalo-Jarvinen H

doi: 10.1111/aos.17453

Macular Diseases

Real-World Efficacy and Durability of Faricimab in Aflibercept-Resistant Neovascular Age-Related Macular Degeneration

J Clin Med

Jeong A, Liang H, Baek SC, Sagong M

doi: 10.3390/jcm14155412

Related content

Risk factors in self-reported dissatisfied patients implanted with various presbyopia-correcting intraocular lenses after cataract surgery

Two-Year Visual, Refractive, and Anatomical Outcomes of Sutureless Intrascleral One-Piece IOL Fixation: A Prospective Study

Intraocular Inflammation (IOI) Associated with Faricimab Therapy: One-year Real World Outcomes

Time to identify glaucoma progression given real-world visual field testing frequencies in a US nationwide insured population

Treatment Regimens with Ranibizumab in Neovascular Age-Related Macular Degeneration: Real-World Results from the PACIFIC Study

Visual outcomes and anatomical biomarkers of Faricimab for diabetic macular edema in the J-CREST real-world comparison of naïve and treated eyes

Real-World Outcomes of Different Types of Treatment for Diabetic Macular Edema Before and After Approval of Anti-Vascular Endothelium Growth Factor Agents

Prototype master protocol for benchmarking of real-world follow-up data in glaucoma

Real-World Efficacy and Durability of Faricimab in Aflibercept-Resistant Neovascular Age-Related Macular Degeneration